clinical trial · NCT04864743
A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Jiangsu Gensciences lnc.·phase1·completed·n = 13
Severe Hemophilia AADVATEFRSW117
brief summary
The primary objectives of the study are to evaluate the Pharmacokinetics，Safety and tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW117) in patients with severe hemophilia A. The secondary objectives are to monitor anti-durg antibodies and anti-PEG antibodies levels in patients with severe hemophilia A
started
Jun 22, 2021
primary completion
Oct 17, 2021
completion
Oct 17, 2021
last updated
Sep 8, 2023
official title
An Open-Label, Multicenter Evaluation of the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW117) in Patients With Severe Hemophilia A.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol